beta amyloid
Alzinova's CEO summarizes 2023 and looks ahead
Alzinova expects to be able to initiate the Phase II study with the vaccine candidate ALZ-101 next year, supported by positive interim data. These...
Intervju
A breakthrough in Alzheimer's drug development?
While Alzheimer's disease constitutes an increasingly...